Estrogen Receptor Positive Breast Cancer is the most common type of breast cancer diagnosed in the world. American Cancer Society has found that approximately two out of every three cases of breast cancer are hormone receptor positive. Approximately, 75% of cases of breast cancer are ER- Positive Breast Cancer and the American Association Society estimates that there will be approximately 246,660 new cases of ER- Positive Breast Cancer and 2,600 new cases among men in 2016.

There are approximately 6 marketed drugs that have been approved for the treatment of ER-Positive Breast Cancer. Among them, Ibrance received approval in 2015 by USFDA. It is a blockbuster drug for Pfizer with annual sales of USD 723 million.  Other drugs such as Evista, Aromasin and Fareston were approved before 2000. Halaven and Taxotere were approved by US FDA in November 2010. Halaven has highest sales as compared to the other drugs.

Market of ER-Positive Breast Cancer is estimated to be 2.86 billion in coming future. Pipeline of ER- Positive Breast cancer is very profuse.  AstraZeneca plc, GlaxoSmithKline, and Novartis Pharmaceuticals are developing drugs such as AZD4547, GSK525762 and Entinostat for the treatment of ER-Positive Breast Cancer.

Despite of availability of effective treatment, survival rates are low in Stage IV as compared to other stages. Other problems such as multidrug resistance and intra-tumor heterogeneity are associated with existing treatment. Thus, there is a need of substantial efforts for finding new treatments for ER- positive Breast Cancer.


Insight by:
Diksha Wadhwa
Associate Analyst
DelveInsight Buisness Research